التفاصيل البيبلوغرافية
| العنوان: |
An Overview of Renal Cell Carcinoma Hallmarks, Drug Resistance, and Adjuvant Therapies. |
| المؤلفون: |
DA SILVA PRADE, JOSIELE, SOARES DE SOUZA, RUAN, DA SILVA D'AVILA, CAMILA MEDIANEIRA, CORREIA DA SILVA, THAYLINE, CASSEL LIVINALLI, ISADORA, ZANINI BERTONCELLI, ANA CLARA, KRAPF SACCOL, FERNANDA, DE OLIVEIRA MENDES, TALLYS, GINDRI WENNING, LARISSA, DA ROSA SALLES, THEODORO, BOHN RHODEN, CRISTIANO RODRIGO, CARLA CADONA, FRANCINE |
| المصدر: |
Cancer Diagnosis & Prognosis; Nov/Dec2023, Vol. 3 Issue 6, p616-634, 19p |
| مصطلحات موضوعية: |
DRUG resistance, NATURAL products, KIDNEY tumors, PROTEIN-tyrosine kinase inhibitors, MULTIDRUG resistance |
| مستخلص: |
Renal neoplasms are highlighted as one of the 10 most common types of cancer. Renal cell carcinoma (RCC) is the most common type of renal cancer, considered the seventh most common type of cancer in the Western world. The most frequently altered genes described as altered are VHL, PBRM1, SETD2, KDM5C, PTEN, BAP1, mTOR, TP53, TCEB1 (ELOC), SMARCA4, ARID1A, and PIK3CA. RCC therapies can be classified in three groups: monoclonal antibodies, tyrosine kinase inhibitors, and mTOR inhibitors. Besides, there are targeted agents to treat RCC. However, frequently patients present side effects and resistance. Even though many multidrug resistance mechanisms already have been reported to RCC, studies focused on revealing new biomarkers as well as more effective antitumor therapies with no or low side effects are very important. Some studies reported that natural products, such as honey, epigallocatechin-3-gallate (EGCG), curcumin, resveratrol, and englerin A showed antitumor activity against RCC. Moreover, nanoscience is another strategy to improve RCC treatment and reduce the side effects due to the improvement in pharmacokinetics and reduction of toxicities of chemotherapies. Taking this into account, we conducted a systemic review of recent research findings on RCC hallmarks, drug resistance, and adjuvant therapies. In conclusion, a range of studies reported that RCC is characterized by high incidence and increased mortality rates because of the development of resistance to standard therapies. Given the importance of improving RCC treatment and reducing adverse effects, nanoscience and natural products can be included in therapeutic strategies. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancer Diagnosis & Prognosis is the property of International Institute of Anticancer Research and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
